Phase 3 HIV and AIDS Trial, Recruiting NCT06507059 Sponsor: Chang Gung Memorial Hospital Condition: HIV and AIDS
Back to Hiv Aids

Phase 3 HIV and AIDS Trial, Recruiting

NCT06507059
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older who are willing to sign a written consent form, both male and female.
  • People who have been diagnosed with HIV for at least 12 months at the time of joining the trial.
  • People who are on oral HIV treatment (even if taken irregularly or with breaks), with a recent viral load test result showing 200 copies/mL or higher.
  • People who weigh at least 35 kilograms.
  • People who are willing to stay in contact with the research team throughout the study by providing a working phone number, social media contact (such as Line), or contact details for a family member or friend.
  • People who are willing to receive drug injections into the buttocks.
  • People who are willing to switch back to oral medication, or follow the nationally recommended treatment guidelines, after the injectable treatment in this trial ends.

Who may not be able to join:

  • People who are currently on oral HIV treatment but have only been taking it (or restarting it) for less than six months in a row before the screening visit.
  • People who have previously had HIV drug resistance testing and are known to have resistance to either cabotegravir or rilpivirine (the drugs used in this trial).
  • People who are unable to stay in regular contact with the research team throughout the study.
  • People who carry the hepatitis B virus and for whom hepatitis B treatment cannot be provided during the period of switching to the long-acting injectable medication.
  • People who have buttock fillers.
  • Women who are pregnant, breastfeeding, or planning to become pregnant during the trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Nan-Yu Chen, MD, PhD, Chang Gung Memorial Hospital

Phone: +886 3 3281200

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
19 July 2024
Est. completion
1 July 2025

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

HIV-1 RNA <200 copies/mL

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov